title: Use of buserelin to induce ovulation in the cyclic mare.
abstract: Inducing ovulation in a cyclic mare is often necessary. For this purpose, hCG has been used commonly, but the response can be reduced after successive administrations. The aims of this study were to test the effectiveness of buserelin in hastening ovulation in estrus mares, and its influence on fertility; and to investigate the effect of treatment on LH secretion. Five crossover trials were designed to compare the effect of two treatments: buserelin (40 microg in 4 doses i.v. at 12 h intervals) vs placebo (Experiments 1 and 2); buserelin 40 microg (in 4 doses i.v.) vs 20 microg (Experiment 3); buserelin (4 doses of 20 microg i.v.) vs hCG (1 dose of 2,500 IU i.v.) (Experiment 4); or buserelin (3 doses of 13.3 microg at 6 h interval) vs hCG (Experiment 5). In Experiment 2, blood samples were taken hourly until ovulation, for LH measurements. In Experiment 1, buserelin treatment significantly hastened ovulation. Reduction of the dose by half (Experiment 3) did not alter the effectiveness. In Experiments 4 and 5, buserelin was as effective as hCG in inducing ovulation between 24 and 48 h after initiation of treatment. Buserelin treatment induced a rise in LH concentration during the 48 h period of the experiment, and LH concentrations before ovulation were significantly higher in buserelin treated cycles than in placebo cycles. These experiments demonstrated the usefulness of two new protocols of administration of buserelin, as an alternative to hCG for induction of ovulation. One hypothesis explaining the mechanism of action is that the persistant rise in LH concentration could modify the ratio of biological/immunological LH, as it occurs physiologically, thereby hastening ovulation.
authors.affiliation: Department of Reproduction, Veterinary School, Nantes, France.
authors.forename: I
authors.initials: I
authors.lastname: Barrier-Battut
authors.forename: N
authors.initials: N
authors.lastname: Le Poutre
authors.forename: E
authors.initials: E
authors.lastname: Trocherie
authors.forename: S
authors.initials: S
authors.lastname: Hecht
authors.forename: A
authors.initials: A
authors.lastname: Grandchamp des Raux
authors.forename: J L
authors.initials: JL
authors.lastname: Nicaise
authors.forename: X
authors.initials: X
authors.lastname: Vérin
authors.forename: J
authors.initials: J
authors.lastname: Bertrand
authors.forename: F
authors.initials: F
authors.lastname: Fiéni
authors.forename: R
authors.initials: R
authors.lastname: Hoier
authors.forename: A
authors.initials: A
authors.lastname: Renault
authors.forename: L
authors.initials: L
authors.lastname: Egron
authors.forename: D
authors.initials: D
authors.lastname: Tainturier
authors.forename: J F
authors.initials: JF
authors.lastname: Bruyas
mesh_terms: D000818:Animals; D001947:Breeding / Q000379:methods*; D002064:Buserelin / Q000008:administration & dosage / Q000494:pharmacology*; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D018592:Cross-Over Studies; D004334:Drug Administration Schedule / Q000662:veterinary; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000494:pharmacology*; D006736:Horses / Q000502:physiology*; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction / Q000379:methods*; D013997:Time Factors
chemical_list: D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D007986:Luteinizing Hormone; D002064:Buserelin